<DOC>
	<DOCNO>NCT01635296</DOCNO>
	<brief_summary>This multi-center , open-label , Phase 1b study evaluate safety , pharmacokinetics efficacy RO5045337 combination cytarabine patient acute myelogenous leukemia . In Arm A , cohorts previously untreated patient deem unsuitable standard induction therapy receive escalate oral dos RO5045377 cytarabine 20 mg/m2 subcutaneously daily Days 1 10 28-day cycle . In Arm B , cohorts patient relapsed refractory least one cytarabine/anthracycline contain regimen receive escalate oral dos RO5045377 Days 1 5 cytarabine 1 gm/m2 intravenously Days 1 6 28-day cycle . Patients receive 4 cycle therapy , patient Arm A achieve hematologic response may continue additional cycle disease progression .</brief_summary>
	<brief_title>A Study RO5045337 Combination With Cytarabine Patients With Acute Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Patients histologically cytologically document acute myelogenous leukemia appropriate cytarabine therapy include : Arm A : Patients receive prior standard induction chemotherapy , consider unsuitable standard induction therapy Arm B : Patients fail 1st great line standard induction chemotherapy ( primary refractory ) patient originally achieve complete response currently first great relapse Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 All nonhematological adverse event prior chemotherapy , surgery , radiotherapy must resolve NCICTC AE Grade &lt; /=2 Adequate hepatic renal function Patient must willing submit blood sample bone marrow sample PK PD analyse exploratory biomarkers History allergic toxic reaction attribute cytarabine history allergic reaction component formulate product Current evidence CNS leukemia Any severe and/or uncontrolled medical condition condition could affect participation study Pregnant breastfeed woman HIVpositive patient receive combination antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>